Banco Santander SA vs Twist Bioscience Corp — how do they compare? Banco Santander SA trades at $13.7 (market cap $191.46B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Banco Santander SA is far larger — about 35.1× Twist Bioscience Corp's market cap, and Banco Santander SA pays a 2.09% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SAN | TWST | |
|---|---|---|
Market Cap | $191.46B | $5.45B |
Sector | Financials | Health |
52-Week High | $14.37 | $102.88 |
52-Week Low | $8.40 | $24.16 |
Dividend Yield | 2.09% | — |
Enterprise Value | — | $5.37B |
Signals from Pluang's Aura AI — not financial advice
Santander (SAN) trades at $13.65, up 0.74% with mixed technical signals showing bearish moving averages but oversold RSI. The company reported Q1 2026 EPS beat ($0.41 vs $0.29 expected) and maintains strong profitability with 26.72% net margin and 16.18% ROE. Recent developments include the $12.2 billion Webster Bank acquisition and AI-driven cost initiatives targeting $1.15 billion in business value.
SAN offers value with a 13.23 P/E and dividend yield near 4.4%, supported by 64% analyst buy ratings. Key risks include declining cash flows (-$28.13B in 2024) and Spanish antitrust probes. The stock's upside depends on successful integration of acquisitions and AI efficiency gains offsetting macroeconomic pressures on European banking.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →